TSVT

2seventy Bio, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website 2seventybio.com
Employees(FY) 425
ISIN US9013841070

Performance

+8.23%

1W

-1.23%

1M

-20.0%

3M

+126.95%

6M

+12.41%

YTD

-58.04%

1Y

Profile

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of TSVT 2024-05-10

Overview:

In analyzing the technical indicators for TSVT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.

Trend In...

See more ...

Recent News & Updates

2024-05-12 03:24
5 Penny Stocks with Insider Buying in 2024(Insidermonkey)
2024-05-07 23:57
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-07 20:15
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-07 19:00
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress(Businesswire)
2024-05-02 19:00
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024(Businesswire)
2024-04-23 22:01
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?(Zacks)
2024-04-16 23:02
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why(Zacks)
2024-04-04 21:05
U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy(Businesswire)
2024-03-31 19:30
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron(Businesswire)
2024-03-20 05:04
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors(Businesswire)
2024-03-15 06:27
FDA Advisory Committee Votes in Favor of Bristol Myers Squibbs and 2seventy bios Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy(Businesswire)
2024-03-06 20:10
2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-04 18:53
TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-04 18:00
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress(Businesswire)
2024-03-03 19:56
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?(Zacks)
2024-02-29 18:00
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences(Businesswire)
2024-02-26 19:00
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise(Newsfilecorp)
2024-02-05 03:05
2seventy bio to Participate in Upcoming Investor Conferences(Businesswire)
2024-02-04 17:59
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study(Businesswire)
2024-01-31 19:27
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?(Zacks)
2024-01-30 22:11
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up(Zacks)
2024-01-29 18:01
2seventy bio Announces New Strategic Path Forward(Businesswire)
2024-01-11 23:00
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy(Zacks)
2023-12-11 06:30
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3(Businesswire)
2023-12-10 18:00
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)(Businesswire)
2023-12-06 01:00
2seventy bio Reiterates Commitment to Maximizing Shareholder Value(Businesswire)
2023-11-19 23:02
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug(Investopedia)
2023-11-19 17:59
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma(Businesswire)
2023-11-13 18:00
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress(Businesswire)
2023-11-09 18:00
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023(Businesswire)

Page 1 of 3

previousnext